**Lactose (India) reported a standalone net profit of ₹2.37 crore for the quarter ended June 2026, representing a significant 58% increase from ₹1.50 crore recorded in the corresponding quarter of the previous year. According to reports from Business Standard, this substantial profit growth demonstrates the company's improved operational efficiency and financial performance during the first quarter of the current fiscal year. The company's basic earnings per share (EPS) stood at ₹1.88, up from ₹1.19 in Q1FY25, reflecting strong bottom-line performance across all key financial metrics.
The company's sales revenue increased by 18.67% to ₹46.97 crore in Q1 FY2026 compared to ₹39.58 crore in the same quarter of the previous financial year. As reported by Business Standard, this revenue growth indicates strong market demand and effective business expansion strategies implemented by the company during the quarter. The revenue from operations rose 19% year-on-year to ₹4,696.84 lakh, reflecting robust operational performance in the pharmaceutical segment, with total income growing by 18.8% to ₹4,752.82 lakh. This performance aligns with broader sector trends showing double-digit revenue growth across consumer-focused sectors including automobiles and consumer goods, driven by sustained market demand.
The company's operating profit margin (OPM) stood at 12.94% in the June 2026 quarter, compared to 11.29% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this improvement in OPM reflects better cost management and operational efficiency during the quarter. Despite higher input costs, the company managed to expand its pre-tax profit to ₹323.32 lakh from ₹228.87 lakh in the prior year period, demonstrating effective cost optimization strategies. However, the company faced sector-wide challenges with aggregate margins shrinking by 210 basis points to 14.4% due to input cost pressures affecting various sectors.
The company faced significant cost inflation with cost of materials consumed increasing by over 100% to ₹3,249.18 lakh compared to ₹1,563.63 lakh in Q1FY25, representing a substantial increase in input costs. However, the company successfully managed these pressures by optimizing other expense lines, with total expenses growing at a slower rate of 17.5% compared to revenue growth of 18.7%, leading to an expansion in pre-tax profits. In a separate corporate action, the Board approved the forfeiture of ₹652.50 lakh from expired warrants, representing 25% of the issue price, which has been transferred to Capital Reserve in compliance with SEBI regulations. The company's experience mirrors broader sector challenges where higher input costs put pressure on sector's aggregate margin across various industries.
The company continues to pursue strategic consolidation through its Scheme of Arrangement for merger with Vitanosh Ingredients Private Limited. The scheme was approved by shareholders at the Extraordinary General Meeting held on March 28, 2026, and is currently pending final approvals from the Securities and Exchange Board of India and the National Company Law Tribunal. No accounting effect of the merger has been recognized in the current quarter's financials, with the company maintaining its standalone operations while pursuing this strategic consolidation initiative.
